Evaluation of patient frailty: Quality of Life questionnaire
Study summary
Fibrosing interstitial lung diseases (ILDs), with idiopathic pulmonary fibrosis being the most common form, primarily affect older individuals and have a poor prognosis, with a median survival of 3 to 5 years. While antifibrotic treatments such as nintedanib and pirfenidone can slow disease progression, their efficacy is often limited by side effects, particularly in elderly patients. A comprehensive patient assessment, including evaluations of frailty and sarcopenia, could optimize care by identifying those at risk for poor outcomes or poor treatment tolerance. Frailty, characterized by reduced physiological reserves, and sarcopenia, defined as a loss of muscle mass and strength, are both associated with increased mortality and morbidity risks. Although their individual impacts on fibrosing ILDs have been documented, the combined effect of these two syndromes on patient prognosis remains unexplored, highlighting the need for further studies to guide therapeutic decision-making.
Eligibility
Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patient with fibrosing ILD according to the ATS/ERS/JRS/ALAT 2022 criteria.
* Patient aged ≥ 65 years.
* Outpatient consultation (scheduled appointment in an outpatient clinic, day hospital, or weekly hospital stay).
* French-speaking patient.
* Patient who has received an information sheet explaining the study and has not expressed opposition to participating in this research.
Exclusion Criteria:
* Patient under legal guardianship, curatorship, or judicial protection.
* Cognitive disorders limiting the use of questionnaires.
* Patient with a CT scan showing an early usual interstitial pneumonia (UIP) pattern according to the ATS/ERS/JRS/ALAT 2022 classification.
Primary outcome measure(s)
to analyze the prognostic value of the phenotypes "frail and sarcopenic," "frail only," "sarcopenic only," and "robust" on the outcomes of patients with fibrosing ILDs — 12 months association between the classifications "non-frail," "frail" (according to the Fried score- percentage of patients), "sarcopenic" (based on EWGSOP criteria - percebntage of patients), and "frail and sarcopenic" at the initial evaluation of ILD (percentage of patients)
to analyze the progression of sarcopenia — up to 12 months composite outcome comprising death, hospitalization, or progression of fibrosing ILD (percentage of patients)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
